FDA Accepts Valneva’s Chikungunya Vaccine License Application for Priority Review

NewsDesk @bactiman63 Specialty vaccine company, Valneva, announced that the U.S. Food and Drug Administration (FDA) has completed a filing review of its Biologics License Application for Valneva's single-shot chikungunya vaccine candidate VLA1553 and has determined that the application is sufficiently complete to permit a substantive review. The review classification is Priority. VLA1553 has been assigned a Prescription [...]

The post FDA Accepts Valneva's Chikungunya Vaccine License Application for Priority Review appeared first on Outbreak News Today.